under compassionate access for ABD- 3001 in relapse and refractory T-cell cell acute lymphoblastic leukemia.
Advanced BioDesign, a French clinical-stage biotechnology company focused on developing innovative therapies for treatment-resistant cancers, today announced that the first patient in France has been treated with its lead investigational drug, ABD-3001, under a compassionate access authorization for relapsed and refractory (R/R) T-cell acute lymphoblastic leukemia (T-ALL).
